drugset / Trial / NCT03160820
Study on Immunization Schedule of Beijing Tiantan Biological's Measles-mumps-rubella(MMR) Vaccine
Phase 4
Completed
873 enrolled
Centers for Disease Control and Prevention, China
Beijing Tiantan Biological Products Co., Ltd. · collab
Non-randomizedParallel-groupSingle-blindPrevention
Summary
This study will evaluate the immunogenicity and safety of Beijing Tiantan's MMR vaccine in subjects 18 months of age and older. The MMR vaccine may be administered as a second dose to 4-6 year-old persons with one dose immunization with MMR vaccine or as a first dose to 18 month-old subjects with one dose immunization with measles-rubella(MR).
Timeline
- Start
- 2016-03
- Primary completion
- 2016-12
- Completion
- 2017-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Measles, mumps and rubella Combined Vaccine, Live | Vaccine | — | — |